Prognostic factors in soft tissue sarcoma: Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence

Acta Orthopaedica Scandinavica, Supplement

Volumn 75, Issue 314, 2004, Pages

  Engellau, Jacob ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BIOLOGICAL MARKER; COMPLEMENTARY DNA; CYCLIN A; DOXORUBICIN; GLYCOPROTEIN P; HERMES ANTIGEN; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE CANCER; SOFT TISSUE SARCOMA; TISSUE MICROARRAY; TISSUE NECROSIS; ARTICLE; CHEMISTRY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SARCOMA; TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; TIME FACTORS; TISSUE ARRAY ANALYSIS;

EID: 13744252792     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (194)

1. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350: 1647-54, 1997.
2. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst Rev: CD001419, 2000.
3. Ahlen J, Weng WW, Brosjo O, et al. Evaluation of immunohistochemical parameters as prognostic markers in malignant fibrous histiocytoma. Oncol Rep 10: 1641-5, 2003.
4. Allander SV, Illei PB, Chen Y, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161: 1587-95, 2002.
5. Alvegard TA, Berg NO, Baldetorp B, et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 8: 538-47, 1990.
6. Angervall L, Kindblom LG, Rydholm A, et al. The diagnosis and prognosis of soft tissue tumors. Semin Diagn Pathol 3: 240-58, 1986.
7. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-8, 1986.
8. Battifora H, Mehta P. The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-4, 1990.
9. Bauer HC, Trovik CS, Alvegard TA, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 72: 150-9, 2001.
10. Becker RL, Jr., Venzon D, Lack EE, et al. Cytometry and morphometry of malignant fibrous histiocytoma of the extremities. Prediction of metastasis and mortality. Am J Surg Pathol 15: 957-64, 1991.
11. Benassi MS, Ragazzini P, Gamben G, et al. Adhesion molecules in high-grade soft tissue sarcomas: correlation to clinical outcome. Eur J Cancer 34: 496-502, 1998.
12. Billingsley KG, Lewis JJ, Leung DH, et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85: 389-95, 1999.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-10, 1986.
14. Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39: 64-9, 2003.
15. Bolard P, Quantin C, Esteve J, et al. Modelling time-dependent hazard ratios in relative survival: application to colon cancer. J Clin Epidemiol 54: 986-96, 2001.
16. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 9: 1941-56, 2003.
17. Broders AC HR, Meyerding HW. Pathological features of soft tissue sarcoma. Surg Gynecol Obstet: 267-80, 1939.
18. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-6, 1999.
19. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-9, 2000.
20. Choong PF, Akerman M, Willen H, et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation - a marker of metastasis? Apmis 102: 915-24, 1994.
21. Cichy J, Pure E. The liberation of CD44. J Cell Biol 161: 839-43, 2003.
22. Clasby R, Tilling K, Smith MA, et al. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 84: 1692-6, 1997.
23. Coindre JM. Symposium 14: Controversial topics in soft tissue pathology. Histopathology 41: 227-248, 2002.
24. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14: 869-77, 1996.
25. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91: 1914-26, 2001.
26. Coley HM, Verrill MW, Gregson SE, et al. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer 36: 881-8, 2000.
27. Collin F, Chassevent A, Bonichon F, et al. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group. Cancer 79: 2371-9, 1997.
28. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109: 987-91, 2002.
29. Coradini D, Daidone MG, Boracchi P, et al. Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol 18: 2702-9, 2000.
30. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-9, 1994.
31. Costa J (1990) The grading and staging of soft tissue sarcomas. Pathobiology of Soft Tissue Tumors, ed. C. Fletcher and P. McKee Edinburgh, UK: Churchill Livingstone.
32. Costa J, Wesley RA, Glatstein E, et al. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 53: 530-41, 1984.
33. Costa MJ, Weiss SW. Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome. Am J Surg Pathol 14: 1126-32, 1990.
34. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 13: 115-23, 2003.
35. Dahlen A, Fletcher CD, Mertens F, et al. Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol 164: 1645-53, 2004.
36. Dan'ura T, Kawai A, Morimoto Y, et al. Apoptosis and expression of its regulatory proteins in soft tissue sarcomas. Cancer Lett 178: 167-74, 2002.
37. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated reciever operating curves: A nonparametric approach. Biometrics 44: 837-845, 1988.
38. Donato Di Paola E, Nielsen OS. The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38 Suppl 4: S138-41, 2002.
39. Drobnjak M, Latres E, Pollack D, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 86: 549-54, 1994.
40. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop (153): 106-20, 1980.
41. Eriksson M, Hardell L, Adami HO. Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study. J Natl Cancer Inst 82: 486-90, 1990.
42. Fernberg JO, Hall KS. Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand (Suppl 311) 75: 77-86, 2004.
43. Fernebro E, Dictor M, Bendahl PO, et al. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126: 702-5, 2002.
44. Figueredo A, Bramwell V, Bell RS, et al. 2002 Oct.: Toronto (ON): Cancer Care Ontario (CCO). p. 27.
45. Fleming JB, Berman RS, Cheng SC, et al. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 17: 2772-80, 1999.
46. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16: 213-28, 1992.
47. Fletcher CD, Gustafson P, Rydholm A, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19: 3045-50, 2001.
48. Fletcher CDM, Unni KK, Mertens FE, (2002) Pathology and Genetics of Tumours of Soft Tissue and Bone. World Health Organisation Classification of Tumours, ed. C.D.M. Fletcher, K.K. Unni, and F. Mertens. Lyon: IARC Press.
49. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19: 1238-47, 2001.
50. Gebauer G, Fehm T, Lang N, et al. Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat 75: 167-73, 2002.
51. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37: 1096-103, 2001.
52. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
53. Greene FL, Page DL, Fleming ID, et al., eds. (2002) AJCC Cancer Staging Handbook/American Joint Committee on Cancer. 6th. edition, ed. F.L. Greene, Springer-Verlag: New York, Berlin, Heidelberg.
54. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15: 350-62, 1997.
55. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259: 1-31, 1994.
56. Gustafson P, Akerman M, Alvegard TA, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer 39: 1568-76, 2003.
57. Gustafson P, Baldetorp B, Ferno M, et al. Prognostic implications of various models for calculation of S-phase fraction in 259 patients with soft tissue sarcoma. Br J Cancer 79: 1205-9, 1999.
58. Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 65: 47-50, 1994.
59. Gustafson P, Rooser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 67: 2083-6, 1991.
60. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137, 2000.
61. Hasegawa T, Yamamoto S, Yokoyama R, et al. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 95: 843-51, 2002.
62. Hasegawa T, Yokoyama R, Lee YH, et al. Prognostic relevance of a histological grading system using MIB-1 for adult soft-tissue sarcoma. Oncology 58: 66-74, 2000.
63. Hasegawa T, Yokoyama R, Matsuno Y, et al. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 32: 257-63, 2001.
64. Hashimoto H, Daimaru Y, Takeshita S, et al. Prognostic significance of histologic parameters of soft tissue sarcomas. Cancer 70: 2816-22, 1992.
65. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-12, 1998.
66. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 3: 685-94, 2003.
67. Heslin MJ, Cordon-Cardo C, Lewis JJ, et al. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 83: 490-7, 1998.
68. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52: 227-37, 1998.
69. Hollowood K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Semin Diagn Pathol 12: 210-20, 1995.
70. Hollstein M, Hergenhahn M, Yang Q, et al. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 431: 199-209, 1999.
71. Hoos A, Nissan A, Stojadinovic A, et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 8: 3841-9, 2002.
72. Hoos A, Stojadinovic A, Mastorides S, et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92: 869-74, 2001.
73. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158: 1245-51, 2001.
74. Hoppin JA, Tolbert PE, Flanders WD, et al. Occupational risk factors for sarcoma subtypes. Epidemiology 10: 300-6, 1999.
75. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 105: 391-402, 2001.
76. Huuhtanen RL, Blomqvist CP, Bohling TO, et al. Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness. Cancer Res 59: 2885-90, 1999.
77. Huuhtanen RL, Blomqvist CP, Wiklund TA, et al. S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome. Cancer 77: 1815-22, 1996.
78. Issels RD, Schlemmer M. Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 49 Suppl 1: S4-8, 2002.
79. Iwaya K, Ogawa H, Kuroda M, et al. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20: 525-9, 2003.
80. Jensen V, Sorensen FB, Bentzen SM, et al. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 32: 536-46, 1998.
81. Jimenez RE, Zalupski MM, Frank JJ, et al. Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86: 976-81, 1999.
82. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3: 655-64, 2002.
83. Kahara N, Ozaki T, Doi T, et al. CD44 expression in soft tissue sarcomas. Virchows Arch 436: 574-8, 2000.
84. Kalbfleisch J, RL. P, (1980) The Statistical Analysis of Failure Time DataNew York, U.S.A.: John Wiley & Sons.
85. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-62, 2001.
86. Karlsson P, Holmberg E, Samuelsson A, et al. Soft tissue sarcoma after treatment for breast cancer-a Swedish population-based study. Eur J Cancer 34: 2068-75, 1998.
87. Kashima T, Nakamura K, Kawaguchi J, et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 104: 147-54, 2003.
88. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20: 791-6, 2002.
89. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338: 153-60, 1998.
90. Kempson RL, Fletcher C, Evans HL, Hendrickson MR, Sibley RK (2001) Tumors of the soft tissues. Vol. Third series, Washington D.C.: Armed Forces Institute of Pathology.
91. Khan J, Simon R, Bittner M, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58: 5009-13, 1998.
92. Kilpatrick SE. Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Ann Diagn Pathol 3: 48-61, 1999.
93. Kindblom LG, Widehn S, Meis-Kindblom JM. The role of electron microscopy in the diagnosis of pleomorphic sarcomas of soft tissue. Semin Diagn Pathol 20: 72-81, 2003.
94. Koea JB, Leung D, Lewis JJ, et al. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol 10: 432-40, 2003.
95. Komdeur R, Klunder J, van der Graaf WT, et al. Multidrug resistance proteins in rhabdomyosarcomas: comparison between children and adults. Cancer 97: 1999-2005, 2003.
96. Komdeur R, Plaat BE, Hoekstra HJ, et al. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 91: 1940-8, 2001.
97. Komdeur R, Plaat BE, van der Graaf WT, et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 39: 909-16, 2003.
98. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-7, 1998.
99. Kuhnen C, Herter P, Muller O, et al. Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod Pathol 13: 1005-13, 2000.
100. Lack EE, Steinberg SM, White DE, et al. Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. J Surg Oncol 41: 263-73, 1989.
101. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62: 135-40, 2002.
102. Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 15: 3249-57, 1997.
103. Lewis JJ, Leung D, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 134: 190-4, 1999.
104. Lynch HT, Deters CA, Hogg D, et al. Familial sarcoma: challenging pedigrees. Cancer 98: 1947-57, 2003.
105. Mandahl N, Mertens F, Panagopoulos I, et al. Genetic characterization of bone and soft tissue tumors. Acta Orthop Scand (Suppl 311) 75: 21-8, 2004.
106. Mandard AM, Petiot JF, Marnay J, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 63: 1437-51, 1989.
107. Markhede G, Angervall L, Stener BA. multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 49: 1721-33, 1982.
108. Maula S, Huuhtanen RL, Blomqvist CP, et al. The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas. Br J Cancer 84: 244-52, 2001.
109. Meis-Kindblom JM, Bjerkehage B, Bohling T, et al. Morphologic review of 1000 soft tissue sarcomas from the Scandinavian Sarcoma Group (SSG) Register. The peer-review committee experience. Acta Orthop Scand Suppl 285: 18-26, 1999.
110. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20: 391-405, 1996.
111. Meric F, Milas M, Hunt KK, et al. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 18: 3378-83, 2000.
112. Miettinen M (2003) Diagnostic Soft Tissue Pathology. 1st ed. Philadelphia: Churchill Livingstone.
113. Miettinen M, Sarlomo-Rikala M, Kovatich AJ. Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours. Virchows Arch 433: 255-60, 1998.
114. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res 462: 247-53, 2000.
115. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 36: 331-4, 2004.
116. Moller Nielsen M Biological characterisation of soft tissue sarcomas - STS. PhD thesis. Faculty of Health Sciences. Odense University. Odense. Denmark p. 207, 2001.
117. Mounier N, Morel P, Haioun C, et al. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. Cancer 82: 1952-62, 1998.
118. Mucci NR, Akdas G, Manely S, et al. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 31: 406-14, 2000.
119. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 116: 221-34, 2004.
120. Myhre-Jensen O, Kaae S, Madsen EH, et al. Histopathological grading in soft-tissue tumours. Relation to survival in 261 surgically treated patients. Acta Pathol Microbiol Immunol Scand [A] 91: 145-50, 1983.
121. Nakanishi H, Myoui A, Ochi T, et al. P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 123: 352-6, 1997.
122. Nakanishi H, Ohsawa M, Naka N, et al. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54: 238-44, 1997.
123. Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. Crit Rev Clin Lab Sci 39: 527-79, 2002.
124. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 163: 1449-56, 2003.
125. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359: 1301-7, 2002.
126. Nilbert M, Meza-Zepeda LA, Francis P, et al. Lessons from genetic profiling in soft tissue sarcomas. Acta Orthop Scand (Suppl 311) 75: 35-50, 2004.
127. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194: 349-57, 2001.
128. O'Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer 17: 1445-55, 1964.
129. Oda Y, Naka T, Takeshita M, et al. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 31: 709-16, 2000.
130. Oda Y, Takahira T, Kawaguchi K, et al. Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol 34: 1035-42, 2003.
131. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359: 2235-41, 2002.
132. Ozzello L SA, Murray MR. Cultural charcteristics of malignant histiocytomas and fibrous xanthomas. Cancer 16: 331-44, 1963.
133. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98: 581-9, 2003.
134. Panagopoulos I, Storlazzi CT, Fletcher CD, et al. The chimeric FUS/CREB312 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer 40: 218-28, 2004.
135. Peiper M, Sato T, Zurakowski D, et al. CD44s expression is associated with improved survival in soft tissue sarcoma. Anticancer Res 24: 1053-6, 2004.
136. Perez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 112: 535-48, 2003.
137. Pezzi CM, Rawlings MS, Jr., Esgro JJ, et al. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer 69: 2098-103, 1992.
138. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 14: 859-68, 1996.
139. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14: 1679-89, 1996.
140. Pisters PW, Pollock RE. Staging and prognostic factors in soft tissue sarcoma. Semin Radiat Oncol 9: 307-14, 1999.
141. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45, 2003.
142. Quantin C, Abrahamowicz M, Moreau T, et al. Variation over time of the effects of prognostic factors in a population-based study of colon cancer: comparison of statistical models. Am J Epidemiol 150: 1188-200, 1999.
143. Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol 4: 695-702, 2003.
144. Ramanathan RC, A'Hern R, Fisher C, et al. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 6: 57-69, 1999.
145. Ray-Coquard I, Thiesse P, Ranchere-Vince D, et al. Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol 15: 307-15, 2004.
146. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157: 787-94, 2000.
147. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 7: 24-31, 2001.
148. Rooser B, Attewell R, Berg NO, et al. Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 61: 817-23, 1988.
149. Rooser B, Willen H, Gustafson P, et al. Malignant fibrous histiocytoma of soft tissue. A population-based epidemiologic and prognostic study of 137 patients. Cancer 67: 499-505, 1991.
150. Ruka W, Emrich LJ, Driscoll DL, et al. Prognostic significance of lymph node metastasis and bone, major vessel, or nerve involvement in adults with high-grade soft tissue sarcomas. Cancer 62: 999-1006, 1988.
151. Rydholm A, Gustafson P. Should tumor depth be included in prognostication of soft tissue sarcoma? BMC Cancer 3: 17,2003.
152. Saito T, Oda Y, Sakamoto A, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 192: 342-50, 2000.
153. Sakamoto A, Oda Y, Adachi T, et al. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 126: 1071-8, 2002.
154. Salo JC, Lewis JJ, Woodruff JM, et al. Malignant fibrous histiocytoma of the extremity. Cancer 85: 1765-72, 1999.
155. Schmitt M, Thomssen C, Ulm K, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306-11, 1997.
156. Schoenfield D. Partial residuals for the proportional hazards regression model. Biometrika 69: 239-241, 1982.
157. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5: 1966-75, 1999.
158. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163: 691-700, 2003.
159. Shapiro L. Beta-catenin and its multiple partners: promiscuity explained. Nat Struct Biol 8: 484-7, 2001.
160. Sherr CJ. Principles of tumor suppression. Cell 116: 235-46, 2004.
161. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96: 5522-7, 1999.
162. Simon MA, Enneking WF. The management of soft-tissue sarcomas of the extremities. J Bone Joint Surg Am 58: 317-27, 1976.
163. Skubitz KM, Skubitz AP. Characterization of sarcomas by means of gene expression. J Lab Clin Med 144: 78-91, 2004.
164. Stamey TA, Donaldson AN, Yemoto CE, et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 160: 2412-7, 1998.
165. Stojadinovic A, Leung DH, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol 20: 4344-52, 2002.
166. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin Surg Oncol 10: 347-56, 1994.
167. Taubert H, Koehler T, Meye A, et al. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol Med 6: 50-9, 2000.
168. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-6, 1999.
169. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-56, 2001.
170. Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 19: 525-34, 2001.
171. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33: 37-42, 1984.
172. Trovik CS. Local recurrence of soft tissue sarcoma. A Scandinavian Sarcoma Group Project. Acta Orthop Scand (Suppl 300) 72: 1-31, 2001.
173. Trovik CS, Bauer HC Local recurrence of soft tissue sarcoma a risk factor for late metastases. 379 patients followed for 0.5-20 years. Acta Orthop Scand 65: 553-8, 1994.
174. van Unnik JA, Coindre JM, Contesso C, et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 29A: 2089-93, 1993.
175. Watanabe T, Oda Y, Tamiya S, et al. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator. Histopathology 39: 187-97, 2001.
176. Weber GF, Bronson RT, Ilagan J, et al. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62: 2281-6, 2002.
177. Weiss SW, Goldblum JR, (2001) Enzinger and Weiss's soft tissue tumors. 4th edition, ed. M. Strauss, St. Louis: C.V. Mosby Co.
178. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 21: 2719-25, 2003.
179. Vermund H, Krajci P, Ejde TJ, et al. Laryngectomy whole organ serial sections-histological parameters correlated with recurrence rate. Acta Oncol 43: 98-107, 2004.
180. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 408: 307-10, 2000.
181. Wong NA, Pignatelli M. Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 160: 389-401, 2002.
182. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18: 2685-94, 2000.
183. Wunder JS, Healey JH, Davis AM, et al. A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 88: 2721-30, 2000.
184. Wurl P, Meye A, Berger D, et al. Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas. Diagn Mol Pathol 6: 249-54, 1997.
185. Wurl P, Meye A, Lautenschlager C, et al. Clinical relevance of pRb and p53 co-overexpression in soft tissue sarcomas. Cancer Lett 139: 159-65, 1999.
186. Wurl P, Meye A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 16: 1183-5, 1998.
187. Xie Y, Skytting B, Nilsson G, et al. The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene 21: 5791-6, 2002.
188. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16: 197-203, 1998.
189. Yang P, Hirose T, Hasegawa T, et al. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. Cancer 76: 618-25, 1995.
190. Zagars GK, Ballo MT. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys 56: 473-81, 2003.
191. Zagars GK, Ballo MT, Pisters PW, et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys 56: 482-8, 2003.
192. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57: 739-47, 2003.
193. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 97: 2530-43, 2003.
194. Zahm SH, Fraumeni JF, Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 24: 504-14, 1997.